Blandt patienter med Crohns sygdom, der fik vedligeholdelsesbehandling, udviklede cirka 6- 13% antistoffer overfor infliximab.
Of Crohn's disease patients who received maintenance treatment, approximately 6-13% developed antibodies to infliximab.